OS
Operating Division	OPDIV Contact	OPDIV Phone	Sequence Num	Solicitation Release Qtr	Procurement Method	Procurement Category	NAICS	Estimated Cost Range	Description	Incumbant (If any):
OS	Linda Luczak	(202)-260-0271	HHS-OS-0004	4th Qtr FY2009	Full & Open	Research & Development	325412	5) $10,000,001 and above	Continuous Supply of Embryonated Eggs and Clinical Batch Production for National Pandemic Influenza Preparedness Efforts- The Department of Health & Human Services (HHS) has a future requirement to support the program’s mission of A Nation Prepared to rapidly respond and produce a strain-matched pandemic influenza vaccine in the event of a declared pandemic. The contract will also support work to produce small clinical lots of inter-pandemic influenza vaccine for potential clinical testing.
OS	Kevin Nilles	(202)-260-1457	HHS-OS-0005	1st Qtr FY2009	Full & Open	Business Services	541711	2) $500,001 to $1,000,000	Immunological Testing of Sera Samples for flu program- To provide serological analysis for human clinical testing of vaccines comprised of H5N1 antigens to support the filing of an investigational New Drug application that will improve U.S. pandemic preparedness.
OS	Kim Hall	(202)-205-1587	HHS-OS-0006	1st Qtr FY2009	Full & Open	Research & Development	339112	4) $5,000,001 to $10,000,000	Advanced Development of Next Generation Portable Ventilators- To support advanced development of domestically manufactured next generation portable ventilators, with accessory components, at a low cost of <$2,000/unit that will advance the technology to provide respiratory support for large numbers of severely ill patients during a pandemic influenza outbreak.
OS	Linda Luczak	(202)-260-0271	HHS-OS-0007	2nd Qtr FY2009	Full & Open	Research & Development	541711	4) $5,000,001 to $10,000,000	Advanced Development of Therapeutics for Treating Neutropenia Resulting from Acute Exposure to Ionizing Radiation -Development and manufacturing of therapeutics on the path to licensure or market approval (i.e., BLA or NDA, respectively) for the indication of treating neutropenia arising from acute exposure to ionizing radiation, (Acute Radiation Syndrome, ARS).
OS	Andre Early	(202)-260-0293	HHS-OS-0008	2nd Qtr FY2009	GSA	Business Services	541612	4) $5,000,001 to $10,000,000	Administrative Support for BARDA
OS	Kim Hall	(202)-205-1587	HHS-OS-0009	2nd Qtr FY2009	Full & Open	Research & Development	325414	5) $10,000,001 and above	Advanced Development of Recombinant Influenza Vaccine Products & Manufacturing Capabilities for Pandemic Preparedness- To perform advanced development and manufacturing of a recombinant influenza vaccine product that could be rapidly made available in the event of a pandemic influenza outbreak.
OS	Glynis Fisher	(202)-260-1880	HHS-OS-0010	2nd Qtr FY2009	Full & Open	Research & Development	325414	4) $5,000,001 to $10,000,000	Broad Agency Announcement(BAA)- Advance the knowledge and scientific understanding of Chemical Biological Radiological and Nuclear (CBRN)candidate acquisition programs toward eventual FDA approval in the research areas of vaccines, antitoxins and Therapeutics, antimicrobials and antivirals, radiological and nuclear countermeasures, chemical agent countermeasures and diagnostics.
OS	Carl Newman	(202)-205-1156	HHS-OS-0001	2nd Qtr FY2009	Full & Open	Research & Development	541711	5) $10,000,001 and above	Broad Agency Announcement(BAA)-"Point of Care or High-Throughput Biological Assays for Determining Absorbed Ionizing Radiation Dose (Biodosimetry)After Radiologic and Nuclear Events"
OS	Brenda Brooks	(202)-260-1460	HHS-OS-0002	3rd Qtr FY2009	To be determined	Research & Development	325414	5) $10,000,001 and above	Anthrax Antimicrobial MedKit for Adult and Family usage- This project supports the design of an anthrax antimicrobial medkit to include a 10 day supply of doxyclycline and appropriate instructions for the use of this medication as approved by the FDA.
OS	Michelle Gray	(202)-260-0950	HHS-OS-0003	2nd Qtr FY2009	Full & Open	Research & Development	325414	5) $10,000,001 and above	Smallpox Antivirals- This requirement shall compliment the existing smallpox preparedness portfolio.